RxDoctor Payments Data

Christian Wunsch

Clinical Pathology · Miami, FLNPI 1124032180

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Abbott accounts for 65.6% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $168 and has fallen 85.7% since, to $24 in 2025.

$235in general payments, 2019–2025

Across 5 payments — averaging $46.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$154
  • Ortho-clinical Diagnostics, Inc.$29
  • Roche Diagnostics Corporation$28
  • AstraZeneca$24
$194,096in research payments, 2019–2025

Across 16 payments — averaging $12,131 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Beckman Coulter, Inc.$194K

What the payments were for

  • Food & beverage$235100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few clinical pathology providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$4,837
Medicare patients
155
Services billed
274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other clinical pathology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →